Batten Disease: Diagnosis, Treatment, and Research

Edited by
Krystyna E. Wisniewski
Nanbert Zhong
New York State Institute for Basic Research in Developmental Disabilities
Staten Island, New York

ACADEMIC PRESS
A Harcourt Science and Technology Company
San Diego  San Francisco  New York
Boston  London  Sydney  Tokyo
Contents

Contributors xi
Preface xiii

1 Neuronal Ceroid Lipofuscinoses: Classification and Diagnosis 1
Krystyna E. Wisniewski, Elizabeth Kida, Adam A. Golabek, Wojciech Kaczmarski, Fred Connell, and Nan Zhong

I. Introduction 3
II. Current Classification of NCLs 10
III. CLN1. Diagnostic Criteria and Phenotype-Genotype Correlation 12
IV. CLN2. Classic Late-Infantile NCL 16
V. CLN3. Juvenile NCL 19
VI. CLN4. Adult NCL 24
VII. CLN5. Finnish Late-Infantile Variant 24
VIII. CLN6. Variant Late-Infantile Gypsy/Indian 25
IX. CLN7. Turkish Variant Late-Infantile NCL 25
X. CLN8. Northern Epilepsy 29
XI. Summary 29
References 30

2 Cellular Pathology and Pathogenic Aspects of Neuronal Ceroid Lipofuscinoses 35
Elizabeth Kida, Adam A. Golabek, and Krystyna E. Wisniewski

I. Introduction 36
II. CLN1. Infantile Form of NCL: Deficiency of Palmitoyl-Protein Thioesterase 1 37
III. CLN2. The Classic Late-Infantile NCL: Deficiency of Tripeptidyl-Peptidase I 42
IV. CLN3. Juvenile Form of NCL: Genetic Defect of Lysosomal Membrane Protein 49
3 Positional Candidate Gene Cloning of CLN1
Sandra L. Hofmann, Amit K. Das, Jui-Yun Lu, and Abigail A. Soyombo

I. Introduction 70
II. Linkage Disequilibrium Mapping of the CLN1 Locus in the Finnish Population 71
III. Palmitoyl-Protein Thioesterase Defines a New Pathway in Lysosomal Catabolism 72
IV. Enzymology of PPT 73
V. Posttranslational Processing and Lysosomal Targeting of PPT 75
VI. The Physiological Role of PPT 77
VII. Palmitoyl-Protein Thioesterase-2 (PPT2) 79
VIII. The PPT cDNA and Gene 79
IX. The Molecular Genetics of CLN1/PPT Deficiency 81
X. Laboratory Diagnosis of PPT Deficiency 86
XI. Prospects for Cause-Specific Treatment of PPT Deficiency 86
References 88

4 Biochemistry of Neuronal Ceroid Lipofuscinoses
Mohammed A. Junaid and Raju K. Pullarkat

I. Introduction 94
II. Genetic Defects 95
III. NCL are Lysosomal Storage Diseases 99
IV. Remaining Issues and Future Directions 101
References 103

5 Positional Cloning of the JNCL Gene, CLN3
Terry J. Lerner

I. Introduction 107
II. CLN3 Maps to Chromosome 16 108
III. A Subunit 9 Gene Is Not CLN3 109
IV. Refined Localization of CLN3 109
References 109
6 Studies of Homogenous Populations: CLN5 and CLN8  123
Susanna Ranta, Minna Savukoski, Pirkko Santavuori, and Matti Haltia

I. Introduction  125
II. Clinical Data  125
III. Neurophysiology  127
IV. Neuroradiology  128
V. Morphology, Cytochemistry, and Biochemistry  128
VI. Molecular Genetics and Cell Biology  132
VII. Diagnosis  135
VIII. Treatment  137
IX. Mouse Homolog for CLN8  137
References  138

7 Molecular Genetic Testing for Neuronal Ceroid Lipofuscinoses  141
Nanbert Zhong

I. Introduction  142
II. Specimens Required for Genetic Testing  143
III. Molecular Genetic Testing for JNCL  144
IV. Molecular Genetic Testing for LINCL and INCL  149
V. Molecular Screening of Carrier Status in NCL Families  151
VI. Prenatal Diagnostic Testing for NCL  152
VII. Important Issues in the Molecular Genetic Testing  154
References  156
8 Genetic Counseling in the Neuronal Ceroid Lipofuscinoses 159
Susan Sklower Brooks
   I. Introduction 159
   II. Inheritance 160
   III. Genetics 160
   IV. Diagnostic Confirmation 161
   V. Genetic Counseling 161
   VI. Carrier Screening 162
   VII. Reproductive Options 164
   VIII. Conclusion 165
   References 166

9 Neurotrophic Factors as Potential Therapeutic Agents in Neuronal Ceroid Lipofuscinosis 169
Jonathan D. Cooper and William C. Mobley
   I. Introduction 170
   II. Mouse Models of NCLs 170
   III. Characterization of the CNS of Mouse Models of NCLs 171
   IV. Neurotrophic Factors as Potential Therapeutic Agents in Neurodegenerative Disorders?—The Neurotrophic Factor Hypothesis 173
   V. NTF Expression and Actions beyond the “Neurotrophic Factor Hypothesis” 176
   VI. Failure of NTF Signaling—A Cause of Neuronal Dysfunction and Degeneration? 177
   VII. Treatment with IGF-1—Implications for the Treatment of NCLs 178
   VIII. Toward Clinical Trials of NTFs 179
   References 179

10 Animal Models for the Ceroid Lipofuscinoses 183
Martin L. Katz, Hisashi Shibuya, and Gary S. Johnson
   I. The Need for Animal Models 184
   II. The Human Disorders 184
   III. Naturally Occurring Ceroid Lipofuscinosis in Animals as Models for the Human Disorders 186
IV. Animal Models Created through Molecular Genetic Manipulation 195
V. Future Directions 198
References 199

11 Experimental Models of NCL: The Yeast Model 205
David A. Pearce

I. Introduction 205
II. Yeast as a Model for JNCL 206
III. What Does Btn1p Do? 210
IV. Yeast as a Therapeutic Model for JNCL 213
V. A Yeast Model for INCL 214
References 215

12 Outlook for Future Treatment 217
Nanbert Zhong and Krystyna E. Wisniewski

I. Molecular Cloning for CLN4, CLN6, and CLN7 218
II. Characterization of Native Substrates for CLN-Encoded Lysosomal Enzymes 218
III. Proteomic Studies of CLN-Encoded Proteins 219
IV. Uncovering the Pathogenesis of the NCLs 219
V. Potential Drugs in Experimental Models May Eventually Lead to Clinical Trials in NCL-Affected Patients 220
VI. Gene Therapy 221
References 222

Appendix: Batten Support Groups 225

United States of America 225
Canadian Chapter 230
European Support Groups 230
Elsewhere 235

Index 237